Mojdeh Saba Heavner

Mojdeh Saba Heavner

Auto-generated profile, based on publicly available information

Mojdeh Saba Heavner

University of Maryland School of Pharmacy Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2020 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
ABAshley Barlow
Ashley Barlow
KLKaitlin M. Landolf
Kaitlin M. Landolf
BBBrooke Barlow
Brooke Barlow
SYSiu Yan Amy Yeung
Siu Yan Amy Yeung
JHJason J. Heavner
Jason J. Heavner
MHMojdeh S. Heavner
Mojdeh S. Heavner

1 April 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
MKMelissa P. Knauert
Melissa P. Knauert
NANajib T. Ayas
Najib T. Ayas
KBKaren J. Bosma
Karen J. Bosma
XDXavier Drouot
Xavier Drouot
MHMojdeh S. Heavner
Mojdeh S. Heavner
Phyllis ZeePhyllis Zee
Phyllis Zee
Background: Sleep and circadian disruption (SCD) is common and severe in the ICU. On the basis of rigorous evidence in non-ICU populations and emerging evidence in ICU populations, SCD is likely to have a profound negative impact on patient outcomes. Thus, it is urgent that we establish research priorities to advance understanding of ICU SCD. Methods: We convened a multidisciplinary group with relevant expertise to participate in an American Thoracic Society Workshop. Workshop objectives included identifying ICU SCD subtopics of interest, key knowledge gaps, and research priorities. Members attended remote sessions from March to November 2021. Recorded presentations were prepared and viewed by members before Workshop sessions. Workshop discussion focused on key gaps and related research priorities. The priorities listed herein were selected on the basis of rank as established by a series of anonymous surveys. Results: We identified the following research priorities: establish an ICU SCD definition, further develop rigorous and feasible ICU SCD measures, test associations between ICU SCD domains and outcomes, promote the inclusion of mechanistic and patient-centered outcomes within large clinical studies, leverage implementation science strategies to maximize intervention fidelity and sustainability, and collaborate among investigators to harmonize methods and promote multisite investigation. Conclusions: ICU SCD is a complex and compelling potential target for improving ICU outcomes. Given the influence on all other research priorities, further development of rigorous, feasible ICU SCD measurement is a key next step in advancing the field.

30 June 2022 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
MHMojdeh S. Heavner
Mojdeh S. Heavner
EGEmily F. Gorman
Emily F. Gorman
DLDustin D. Linn
Dustin D. Linn
SYSiu Yan Amy Yeung
Siu Yan Amy Yeung
TMTodd A. Miano
Todd A. Miano

27 February 2019 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
FAFaith Armstrong
Faith Armstrong
MMMichael T. McCurdy
Michael T. McCurdy
MHMojdeh S. Heavner
Mojdeh S. Heavner

17 October 2020 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
PDF file
CAChristopher D. Adams
Christopher D. Adams
JAJerry Altshuler
Jerry Altshuler
BBBrooke L. Barlow
Brooke L. Barlow
DDDeepali Dixit
Deepali Dixit
CDChristopher A. Droege
Christopher A. Droege
KBKaren Berger
Karen Berger
Evidence‐based management of analgesia and sedation in COVID‐19‐associated acute respiratory distress syndrome remains limited. Non‐guideline recommended analgesic and sedative medication regimens and deeper sedation targets have been employed for patients with COVID‐19 due to exaggerated analgesia and sedation requirements with extended durations of mechanical ventilation. This, coupled with a desire to minimize nurse entry into COVID‐19 patient rooms, marked obesity, altered end‐organ function, and evolving medication shortages, presents numerous short‐ and long‐term challenges. Alternative analgesic and sedative agents and regimens may pose safety risks and require judicious bedside management for appropriate use. The purpose of this commentary is to provide considerations and solutions for designing safe and effective analgesia and sedation strategies for adult patients with considerable ventilator dyssynchrony and sedation requirements, such as COVID‐19.

10 October 2017 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
MHMojdeh S. Heavner
Mojdeh S. Heavner
MZMin Zhang
Min Zhang
CBChelsea E. Bast
Chelsea E. Bast
LPLindsey Parker
Lindsey Parker
RERachel F. Eyler
Rachel F. Eyler